Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

A biobank with fresh and formalin-fixed specimens specializing in neurogenerative disease research.

As lecanemab gains regulatory approval in more countries (see previous story), clinicians are eager to learn from the first centers to have incorporated this therapeutic antibody into their clinical ...

B.A., English, University of Florida M.B.A., American Jewish University Ed.D., Organization of Leadership and Gerontology, Nova Southeastersn University ...

Average Award $300,000-$350,000 based on stage and scope of research. Slightly higher budgets can be considered. One year with potential for follow-on funding.

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Member reports the following financial or other potential conflicts of interest: E. Solje has served on the advisory board of Novartis, EISAI, Lilly and Roche, served as a consult for Novo Nordisk, ...

Jean-François Démonet trained as an MD and Neurologist (1987) at Toulouse University; training in Neuropsychology at Montreal University and in brain imaging in R. Frackowiak’s lab in London UK with a ...